...
首页> 外文期刊>Advances in Bioscience and Clinical Medicine >Changing Landscape of Dysglycemia Management in Critically Ill Patients
【24h】

Changing Landscape of Dysglycemia Management in Critically Ill Patients

机译:重症患者的血糖管理变化趋势

获取原文
   

获取外文期刊封面封底 >>

       

摘要

At present, the body of evidence for blood glucose management in critically ill adults and children is not available beyond the point of proof of efficacy. Intensive blood glucose management did not pass the milestones of effectiveness and efficiency, because the multicenter trials could not confirm the results of the single-center studies. A recent review on the glucose management in critically ill adults and children suggests that use of any drug other than insulin for glucose control in intensive care unit is not recommended (1). As we know, the reason for hyperglycemia is increasing counterregulatory hormones and insulin resistance in the target organs. Thus, in some patients who require high doses of insulin for maintenance of normoglycemia, some concerns such as hypoglycemia could be expected. Additionally, insulin therapy can be associated with hypokalemia and hypomagnesaemia which both promote insulin resistance and higher blood glucose levels. Consequently, administration of further insulin is unavoidable which in turn initiates a vicious cycle with adverse outcomes. One of therapeutic options in these situations is using insulin sensitizing agents as an adjunct therapy for glycemic control in critically ill patients. Different studies have proven that metformin, similar to insulin, is of anti-inflammatory and antioxidant properties, improves lipid profile, decreases nursing workload and lowers the incidence of adverse effects related to high-dose insulin therapy without increased risk of lactic acidosis and hypoglycemia (2-4). Therefore, in patients with refractoriness to insulin who require higher doses of insulin, we might consider metformin as a safe adjunct therapy to reach targeted glucose levels. Another important concern about glucose control in critically ill patients is accuracy of glucose measurement in these patients. The gold standard for blood glucose measurement is performed in a central hospital laboratory with hexokinase or glucose oxidase enzymatic reactions. Hence, for blood glucose management in the ICU, these tests cannot be performed and compromises inevitably have to be made. Many studies recommend that use of capillary instead of arterial blood for blood glucose measurements further amplifies the inaccuracy of blood glucose meters. Based on a meta-analysis, blood glucose measurements in arterial blood on blood gas analyzers are more accurate than in capillary blood on blood glucose meters (5). Accordingly, drawing samples from an indwelling arterial line is the method of choice for frequent blood analysis in adult critical care areas. Sodium chloride 0.9% is the recommended flush solution for maintaining the patency of arterial catheters, but it can be easily confused with glucose-containing bags on rapid visual examination. Unintentional use of a glucose-containing solution results in overestimation of blood glucose concentrations, leads to overtreatment with insulin and finally induces hypoglycaemia and fatal neuroglycopenic brain injury (6). As it remains a common error for incorrect fluids to be administered as arterial line flush infusions, adherence to guidelines about glucose monitoring and insulin administration is necessary for glycemic control in the presence of arterial lines as a standard method for blood sampling during insulin therapy for critically ill patients. Based on mentioned sentences, standardization of the measurement of blood glucose concentrations is necessary. Furthermore, a new perception of hyperglycemia and its management should be assessed in future large trials to elucidate advantages of glucose management in these patients.
机译:目前,除了疗效证明之外,还没有关于危重成年人和儿童血糖管理的证据。严格的血糖管理未达到有效性和效率的里程碑,因为多中心试验无法证实单中心研究的结果。最近对危重成年人和儿童的葡萄糖管理进行的审查表明,不建议在重症监护病房中使用除胰岛素以外的任何药物来控制血糖(1)。众所周知,高血糖的原因是靶器官中反调节激素和胰岛素抵抗的增加。因此,在一些需要大剂量胰岛素维持正常血糖的患者中,可能会出现诸如低血糖等问题。另外,胰岛素疗法可与低钾血症和低镁血症有关,低钾血症和低镁血症均促进胰岛素抵抗和较高的血糖水平。因此,不可避免地要再注射胰岛素,这反过来会引发恶性循环并产生不良后果。在这些情况下,治疗选择之一是使用胰岛素增敏剂作为危重患者血糖控制的辅助治疗。不同的研究已经证明,与胰岛素相似,二甲双胍具有抗炎和抗氧化的特性,可改善血脂状况,减少护理工作量并降低与大剂量胰岛素治疗有关的不良反应的发生率,而不会增加乳酸性酸中毒和低血糖的风险( 2-4)。因此,对于需要更高剂量的胰岛素的胰岛素抵抗患者,我们可以考虑将二甲双胍作为达到目标血糖水平的安全辅助疗法。危重患者血糖控制的另一个重要问题是这些患者的血糖测量准确性。血糖测量的金标准是在中心医院的实验室中通过己糖激酶或葡萄糖氧化酶的酶促反应进行的。因此,对于ICU中的血糖管理,无法执行这些测试,因此不可避免地需要做出折衷。许多研究建议使用毛细管代替动脉血进行血糖测量,这会进一步加剧血糖仪的不准确性。根据荟萃分析,在血气分析仪上对动脉血的血糖测量要比在血糖仪上对毛细血管血的血糖测量更为准确(5)。因此,从留置动脉中抽取样本是成人重症监护区域频繁进行血液分析的一种选择方法。推荐使用0.9%的氯化钠冲洗溶液以保持动脉导管的通畅,但是在快速目测时,它很容易与含葡萄糖的袋子混淆。意外使用含葡萄糖溶液会导致血糖浓度过高估计,导致胰岛素治疗过度,并最终导致低血糖症和致命性神经糖原性脑损伤(6)。由于将不正确的液体作为动脉冲洗液进行输注仍然是一个普遍的错误,因此对于在存在动脉管线的情况下进行血糖控制的血糖控制,必须遵守有关葡萄糖监测和胰岛素给药的指导原则,这是胰岛素治疗期间进行血液采样的标准方法生病的病人。根据提到的句子,必须对血糖浓度的测量进行标准化。此外,应在未来的大型试验中评估对高血糖症及其治疗方法的新认识,以阐明这些患者进行葡萄糖治疗的优势。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号